Waylivra

Indicated For

Familial Chylomicronemia Syndrome (FCS)

About This Medication

# Ionis Pharmaceuticals Patient Assistance Program Guide: How to Get Waylivra (volanesorsen) at Low or No Cost **Waylivra (volanesorsen) is not FDA-approved in the United States, so standard insurance coverage and traditional patient assistance programs are extremely limited.** This guide explains access pathways through manufacturer support, expanded access, and appeals for patients with familial chylomicronemia syndrome (FCS).[1][2] ## About Waylivra (volanesorsen) Waylivra is an antisense oligonucleotide injection that targets apolipoprotein C-III (ApoC-III) to lower triglycerides in adults with FCS, a rare genetic disorder causing extremely high triglyceride levels and recurrent pancreatitis risk. While approved by the European Medicines Agency (EMA) in 2019 for FCS, it lacks U.S. FDA approval, blocking routine insurance coverage and commercial availability.[1][5][7] Ionis Pharmaceuticals (with Akcea Therapeutics) develops it, and European data show it reduces triglycerides effectively, but U.S. access relies on compassionate use or trials.[1][2] **Key facts for patients:** - **Indication:** FCS with triglycerides ≥750 mg/dL despite diet. - **Administration:** Weekly subcutaneous injections. - **Monitoring:** Requires regular platelet counts due to thrombocytopenia risk.[2][7] - **Why it's challenging:** No FDA nod means insurers like Humana or Cigna deny coverage; appeals often fail initially.[1][3] ## Who Qualifies for Assistance? No formal Ionis patient assistance program with defined income thresholds exists publicly, as Waylivra isn't commercially available in the U.S. Eligibility focuses on: - Confirmed FCS diagnosis (genetic testing, triglycerides ≥1,000 mg/dL). - Failure of standard therapies (fibrates, omega-3s, low-fat diet). - Specialist prescription (lipidologist). - Suitability for monitoring (no low platelets ≤140,000/mm³, no pregnancy plans).[1][2][3] **Income eligibility:** Unknown specific thresholds; contact Ionis directly for compassionate use, which may prioritize financial need. Foundations like NORD offer grants for rare diseases.[1] ## Income Eligibility Breakdown | Household Size | FPL % Threshold | Annual Income Limit (2026 est.) | Notes | |---------------|-----------------|-------------------------------|-------| | Individual | Unknown | Unknown | Contact Ionis; no public PAP details.[1] | | Couple | Unknown | Unknown | Rare disease foundations may assist.[1] | | Family of 3 | Unknown | Unknown | State programs possible (e.g., Virginia).[1] | | Family of 4 | Unknown | Unknown | Prioritize clinical urgency over income.[1] | *Table based on lack of standard PAP; programs like expanded access are clinical, not income-based.*[1][2] ## Insurance Requirements **Waylivra is not on any U.S. formulary and requires prior authorization (PA), which is routinely denied due to non-FDA approval.** Medicare, Medicaid, and commercial plans (Humana, Cigna) exclude it. Patients need: - Letter of medical necessity from specialist. - Genetic/clinical proof of FCS. - Documentation of failed therapies. Even with insurance, expect denials; pursue appeals or alternatives.[1][3] **Medicare note:** Part D does not cover non-approved drugs; compassionate use bypasses this.[1] ## Step-by-Step Application Process 1. **Confirm Diagnosis:** Get genetic testing and lipid panel from a lipid specialist. Document recurrent pancreatitis risk.[1][3] 2. **Contact Ionis Pharmaceuticals:** Call or email for expanded access programs (EAP), compassionate use, or trials. Reference APPROACH trial completion if applicable.[1][2] 3. **Submit Insurance PA:** Use provider portal (e.g., Humana/Cigna). Include necessity letter, European data, monitoring plan.[1][3] 4. **Prepare Appeal:** If denied (expected), file internal appeal within deadlines (e.g., 65 days Humana VA).[1] 5. **External Review:** State-specific (e.g., Virginia SCC, Illinois DOI).[1][3] 6. **Explore Foundations:** Apply to NORD or state rare disease programs.[1] 7. **Clinical Trials:** Check clinicaltrials.gov for volanesorsen studies (e.g., NCT03544060 EAP).[2] **Pro tip:** Start with your doctor for peer-to-peer reviews.[1] ## Timeline and Delivery **Processing varies; no standard PAP timeline.** Expanded access: Days to weeks if eligible. Insurance PA: 1-15 days (likely denial). Appeals: 30-65 days internal, 45 days external.[1][3] Delivery via specialty pharmacy (e.g., Accredo) if approved, or direct from manufacturer in EAP.[2][3] | Phase | Timeline | Key Actions | |-------|----------|-------------| | Prep | 0-2 days | Gather docs | | PA Submit | 1-5 days | Insurer review | | Internal Appeal | Up to 65 days | Comprehensive packet | | External | 45 days | State review | | EAP/Trial | Ongoing | Ionis contact[1][2] | ## Alternatives if Denied - **Expanded Access/Compassionate Use:** Ionis/Akcea programs for FCS patients meeting criteria (e.g., prior trial participants).[2] - **Clinical Trials:** Ongoing EAP-like programs.[2] - **Foundations:** NORD, Global Genes for grants.[1] - **Standard Therapies:** Fibrates, omega-3s, strict diet. - **European Travel:** Available in Europe via specialist (not practical).[4][7] ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Waylivra access is highly restricted; consult your doctor and Ionis directly. Program details may change; verify with manufacturer. No guarantees of approval.[1][2]

Program information last verified: March 29, 2026